Accesso Utente

Accedi con il tuo account personale per consultare i materiali riservati

  • Registrati
  • Nome utente dimenticato?
  • Password dimenticata?
  • Non hai ricevuto il link di attivazione?
Key Trials
  • HOME
  • PROGETTO
  • BOARD
  • PUBBLICAZIONI
ACCMED
  • Approfondimenti generali
  • Neoplasie del polmone, Linee Guida AIOM, 2018.
    Planchard D, et al. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv192–iv237
    Postmus PE, et al. Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2017; 28: iv1–iv21.
    ClinicalTrial.gov. A service of the U.S. National Institutes of Health
  • Referenze bibliografiche specifiche
  • Reck M, et al. Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMPOWER150). ESMO 2017, abs LBA1_PR
    Kowanetz M. Socinski M, et al. IMpower150: Efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in 1L Metastatic Nonsquamous NSCLC Across Key Subgroups. AACR Annual Meeting; April 14-18, 2018; Chicago, IL
    Cappuzzo F. Impower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. ESMO 2018 Abs LBA53
© 2016 - 2019 Accademia Nazionale di Medicina - Tutti i diritti riservati
To Top